Literature DB >> 9223669

Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder.

D Cappellen1, S Gil Diez de Medina, D Chopin, J P Thiery, F Radvanyi.   

Abstract

Loss of heterozygosity (LOH) on chromosome 10 has been observed in several human cancers including glioblastomas, meningiomas, melanomas and endometrial and prostate carcinomas. We have investigated the incidence of LOH on chromosome 10 in 36 human transitional cell carcinomas (TCCs) of the bladder, three upper urinary tract TCCs and one lymph node metastasis, using a panel of 27 highly polymorphic markers spanning 10p (short arm) and 10q (long arm). Fourteen bladder tumours (39%), the three upper urinary tract tumours and the lymph node metastasis showed LOH for at least one locus on chromosome 10. Remarkably, LOH on chromosome 10 was observed mainly in muscle-invasive (P = 0.01) and high grade tumours (P = 0.03). For five tumours and the lymph node metastasis, LOH was found at all informative loci, indicating monosomy or isodisomy of chromosome 10. The deletion mapping of the tumours with partial loss delineated two minimal regions of loss on chromosome 10q. One region, the most telomeric, was bounded by markers D10S214 and D10S169 and the other, the most proximal, was bounded by markers D10S222 and D10S531. Our results demonstrate that chromosome 10q LOH is common in muscle-invasive bladder cancers and that two potential tumour suppressor loci, at 10q24.1-q24.3 and 10q26.1-q26.2, may contribute to the malignant progression of these tumours. Localization of the smallest common regions of loss in bladder tumours provides a starting point for the identification of the genes involved.

Entities:  

Mesh:

Year:  1997        PMID: 9223669     DOI: 10.1038/sj.onc.1201154

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  28 in total

Review 1.  The androgen receptor and stem cell pathways in prostate and bladder cancers (review).

Authors:  Katarzyna Marcinkiewicz; Kymora B Scotland; Stephen A Boorjian; Emeli M Nilsson; Jenny Liao Persson; Per Anders Abrahamsson; Cinzia Allegrucci; Ieuan A Hughes; Lorraine J Gudas; Nigel P Mongan
Journal:  Int J Oncol       Date:  2011-09-28       Impact factor: 5.650

2.  Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells.

Authors:  Edmund Chiong; I-Ling Lee; Ali Dadbin; Anita L Sabichi; Loleta Harris; Diana Urbauer; David J McConkey; Rian J Dickstein; Tiewei Cheng; H Barton Grossman
Journal:  Clin Cancer Res       Date:  2011-03-17       Impact factor: 12.531

3.  Identification of a candidate tumor suppressor gene RHOBTB1 located at a novel allelic loss region 10q21 in head and neck cancer.

Authors:  Levent B Beder; Mehmet Gunduz; Mamoru Ouchida; Esra Gunduz; Akiko Sakai; Kunihiro Fukushima; Hitoshi Nagatsuka; Sachio Ito; Noriyasu Honjo; Kazunori Nishizaki; Kenji Shimizu
Journal:  J Cancer Res Clin Oncol       Date:  2005-09-17       Impact factor: 4.553

4.  Genetic deletion and pharmacological inhibition of Akt1 isoform attenuates bladder cancer cell proliferation, motility and invasion.

Authors:  Harika Sabbineni; Abdulrahman Alwhaibi; Anna Goc; Fei Gao; Alanna Pruitt; Payaningal R Somanath
Journal:  Eur J Pharmacol       Date:  2015-07-03       Impact factor: 4.432

5.  Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma.

Authors:  Donna E Hansel; Eric Platt; Mohammed Orloff; Jyoti Harwalker; Swathi Sethu; Jessica L Hicks; Angelo De Marzo; Roxanne E Steinle; Eric D Hsi; Dan Theodorescu; Christina B Ching; Charis Eng
Journal:  Am J Pathol       Date:  2010-04-15       Impact factor: 4.307

6.  Hypermethylation of FOXA1 and allelic loss of PTEN drive squamous differentiation and promote heterogeneity in bladder cancer.

Authors:  Vasty Osei-Amponsa; Jenna M Buckwalter; Lauren Shuman; Zongyu Zheng; Hironobu Yamashita; Vonn Walter; Thomas Wildermuth; Justine Ellis-Mohl; Chang Liu; Joshua I Warrick; Lisa M Shantz; Robert P Feehan; Hikmat Al-Ahmadie; Cathy Mendelsohn; Jay D Raman; Klaus H Kaestner; Xue-Ru Wu; David J DeGraff
Journal:  Oncogene       Date:  2019-10-21       Impact factor: 9.867

Review 7.  Molecular pathogenesis of bladder cancer.

Authors:  Margaret A Knowles
Journal:  Int J Clin Oncol       Date:  2008-08-15       Impact factor: 3.402

8.  Expression of the ZEB1 (deltaEF1) transcription factor in human: additional insights.

Authors:  Elaine M Hurt; Jessica N Saykally; Bynthia M Anose; Kimberly R Kalli; Michel M Sanders
Journal:  Mol Cell Biochem       Date:  2008-07-12       Impact factor: 3.396

Review 9.  Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer.

Authors:  Margaret A Knowles; Fiona M Platt; Rebecca L Ross; Carolyn D Hurst
Journal:  Cancer Metastasis Rev       Date:  2009-12       Impact factor: 9.264

Review 10.  Biology of urothelial tumorigenesis: insights from genetically engineered mice.

Authors:  Xue-Ru Wu
Journal:  Cancer Metastasis Rev       Date:  2009-12       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.